Biomarkers for Alzheimer's disease in plasma, serum and blood - Conceptual and practical problems

Alzheimer's Research and Therapy

Volumn 5, Issue 2, 2013, Pages

  Galasko, Douglas ^a   Golde, Todd E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BLOOD EXAMINATION; DIAGNOSTIC TEST; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SCREENING TEST;

EID: 84873975872     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt164     Document Type: Review

References (25)

1. A prototypical process for creating evidentiary standards for biomarkers and diagnostics. Altar CA, Amakye D, Bounos D, Bloom J, Clack G, Dean R, Devanarayan V, Fu D, Furlong S, Hinman L, Girman C, Lathia C, Lesko L, Madani S, Mayne J, Meyer J, Raunig D, Sager P, Williams SA, Wong P, Zerba K, Clin Pharmacol Therapeutics 2008 83 368 371 10.1038/sj.clpt.6100451 18091762
2. US Food and Drug Administration approval of amyloid imaging. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202008s000lbl.pdf
3. Hypothetical model of dynamic biomarkers of the Alzheimer's disease pathological cascade. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ, Lancet Neurol 2010 9 119 128 10.1016/S1474-4422(09)70299-6 20083042
4. Plasma amyloid-β as a predictor of dementia and cognitive decline: a systematic review. Koyama A, Okerere OI, Yang T, Blacker D, Selkoe DJ, Grodstein F, Arch Neurol 2012 69 824 831 10.1001/archneurol.2011.1841 22451159
5. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Ray S, Britschgi M, Hergbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirami R, Wyss-Coray T, Nat Med 2007 13 1359 1362 10.1038/nm1653 17934472 (Pubitemid 350073592)
6. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM, for the Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project, Arch Neurol 2012 69 1310 1317 22801723
7. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, for the Alzheimer's Disease Neuroimaging Initiative and Australian Imaging Biomarker and Lifestyle Research Group, Arch Neurol 2012 69 1318 1325 22801742
8. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R, Texas Alzheimer's Research & Care Consortium; Alzheimer's Disease Neuroimaging Initiative, PLoS One 2011 6 28092 10.1371/journal.pone.0028092 22163278
9. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H, Alzheimer's Disease Neuroimaging Initiative, Neurology 2012 79 906 914 10.1212/WNL.0b013e318266fc51 22895591
10. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. Johnstone D, Milward EA, Berretta R, Moscato P, Alzheimer's Disease Neuroimaging Initiative, PLoS One 2012 7 34341 10.1371/journal.pone.0034341 22485168
11. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP, Neurosci Lett 2001 304 102 106 10.1016/S0304- 3940(01)01754-2 11335065 (Pubitemid 32377212)
12. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM, Ann Neurol 2009 65 176 183 10.1002/ana.21559 19260027
13. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM, Lancet Neurol 2006 5 655 660 10.1016/S1474-4422(06)70501-4 16857570 (Pubitemid 44062411)
14. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG, Arch Neurol 2007 64 354 362 10.1001/archneur.64.3.354 17353377 (Pubitemid 46425689)
15. Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alpérovitch A, Buée L, Amouyel P, Neurology 2009 73 847 853 10.1212/WNL.0b013e3181b78448 19752451
16. Overlapping profiles of Abeta peptides in the Alzheimer's disease and pathological aging brains. Moore BD, Chakrabarty P, Levites Y, Kukar TL, Baine AM, Moroni T, Ladd TB, Das P, Dickson DW, Golde TE, Alzheimers Res Ther 2012 4 18 10.1186/alzrt121 22621179
17. Plasma clusterin and the risk of Alzheimer disease. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM, JAMA 2011 305 1322 1326 10.1001/jama.2011.381 21467285
18. Association of the Alzheimer's disease clusterin risk allele with plasma clusterin concentration. Schürmann B, Wiese B, Bickel H, Weyerer S, Riedel-Heller SG, Pentzek M, Bachmann C, Williams J, van den Bussche H, Maier W, Jessen F, J Alzheimers Dis 2011 25 421 424 21422520
19. Multiplex serum biomarker assessments:technical and biostatistical issues. Butterfield LH, Potter DM, Kirkwood JM, J Translational Med 2011 9 173 186 10.1186/1479-5876-9-173 21989127
20. Minimizing preanalytical variation of plasma samples by proper blood collection and handling. Yi J, Craft D, Gelfand CA, Methods Mol Biol 2011 728 137 149 10.1007/978-1-61779-068-3-8 21468945
21. Biological and methodological challenges of blood-based proteomics in the field of neurological research. Lista S, Faltraco F, Hampel H, Prog Neurobiol 2013 101-102 18 34 22743551
22. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Rifai M, Gillette MA, Carr SA, Nat Biotech 2006 24 971 983 10.1038/nbt1235 16900146 (Pubitemid 44215392)
23. Validation of a multiplex assay for simultaneous quantification of amyloid-β peptide species in human plasma with utility for measurements in studies of Alzheimer's disease therapeutics. Lachno DR, Emerson JK, Vanderstichele H, Gonzales C, Martényi F, Konrad RJ, Talbot JA, Lowe SL, Oefinger PE, Dean RA, J Alzheimers Dis 2012 32 905 918 22886018
24. Harmonization of immune biomarker assays for clinical studies. van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A, Sci Transl Med 2011 3 108ps44 10.1126/scitranslmed. 3002785 22072636
25. STARDdem homepage. http://www.starddem.org/